Alzecure Pharma Ab · OMXSTO:ALZCUR
Alzecure Pharma Ab — Redeye Theme: Alzheimer's (April 2026)
27 slides from Alzecure Pharma Ab's conference presentation, Apr 9, 2026
Slide 1: Developing therapies for Alzheimer's
April 9, 2026 Developing therapies for Alzheimer’s
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements regarding the Company’s intentions, assessments, or expectations in respect of the Company’s future results, financial position, liquidity, development, prospects, expected growth, strategies and possibilities as well as the market wit
Slide 3: AlzeCure Pharma in brief
AlzeCure Pharma in brief
Slide 4: AlzeCure Pharma – In brief
Introduction AlzeCure Pharma – In brief • Working in Alzheimer’s Disease (AD) & Pain – high unmet medical need & multi-billion sales Professor Jan Lundberg – Board member Former global head of R&D at Eli Lilly & global head potential of research at AstraZeneca joining & investing • Spin-out from Ast
Slide 5: Our Business Model
Introduction Our Business Model Are a Research & Development company Research & develop through early clinical phase and then to out-license or partner on our projects Gain incomes through: Upfront Milestone Royalties on payments payments sold products 5
Slide 6: A pipeline of Small-Molecule Programs
Introduction A pipeline of Small-Molecule Programs Multiple candidates increase chance of success Research Preclinical Phase I Phase II Phase III Platform Candidate Target Indication phase phase Alzheimer’s Disease, Positive allosteric TBI - Traumatic brain Positive read-out Neuro ACD856 modulator (
Slide 7: Focus Area Alzheimer's Disease
Focus Area Alzheimer’s Disease • Cost the society more than oncology, diabetes and cardiovascular diseases TOGETHER!!! • The cost will triple in the next 30 years
Slide 8: Dementia & Alzheimer is a Major Global Concern
Dementia & Alzheimer is a Major Global Concern - A Tripling Patient Population & Cost US$ 3tn 150m 75m 1.5tn 50m 1tn 2020 2030 2050 2020 2030 2050 • 50 million people worldwide live If the total cost for Dementia would with Dementia … be a country based on total cost in 2026, it • … and doubling eve
Slide 9: Only 5-8% of Alzheimer's patients estimated eligible for antibody treatment
Only 5-8% of Alzheimer’s patients* are estimated to be eligible for anti- bodies treatment - Huge unmet medical need remains for alternative Alzheimer’s treatments 9 *) Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging; Rioghna R. Pittock et al; Neurology, 2023;10
Slide 10: Two Alzheimer's platforms - 1st-in-class properties & potential game-changers
Two Alzheimer’s platforms - 1st-in-class properties & potential game-changers MEETING NEEDS OF AD PATIENTS – ADRESSING SHORT TERM NEEDS WITH LONG-TERM BENEFITS Preventive Disease-modifying therapy Symptomatic & pot. Disease-modifying therapy Alzstatin® NeuroRestore® Gamma-secretase modulator Trk-PAM
Slide 11: Alzstatin – gamma-secretase modulator targeting amyloid production
Alzstatin® – gamma-secretase modulator targeting amyloid production for prevention and treatment of Alzheimer’s disease
Slide 12: The Alzheimer's Brain and its Destruction by Toxic Protein
Alzstatin ® – gamma-secretase modulator The Alzheimer’s Brain and its Destruction by Toxic Protein The Amyloid Cascade Toxic protein formations, built up of Aβ42, are harming and destroying brain structures AlzeCure’s GSM1 Alzstatin® reduces Aβ42 to diminish the build-up of toxic fragments & plaque
Slide 13: Alzstatin – Potent Reduction of Toxic Aβ42 & Increasing Protective Aβ37 & Aβ38
Alzstatin ® – gamma-secretase modulator Alzstatin® – Potent Reduction of Toxic Aβ42 & Increasing Protective Aβ37 & Aβ38 Alzstatin® potently reduces the amount of Alzstatin® reduces toxic Aβ42 and Aβ40, while toxic brain Aβ42 in animals increasing protective Aβ38 and Aβ37 peptides Αβ42 150 3000 % of
Slide 14: New preclinical data shows Induced Plaque Regression
Alzstatin ® – gamma-secretase modulator New preclinical data shows Induced Plaque Regression Two-photon-study preclinical study in APP/PS1 mice Vehicle AZ4126 Day 0 Day 28 Day 0 Day 28 Distribution of plaque growth & Plaque appearance or regression disappearance 28-day GSM treatment Reduces amyloid
Slide 15: Multiple Potential Treatment Populations for Alzstatin
Alzstatin ® – gamma-secretase modulator Multiple Potential Treatment Populations for Alzstatin – Maintenance, Combination & Preventive Therapy Maintenance therapy - in patients with established Alzheimer’s disease • Treatment after initial plaque clearance by monoclonal antibody treatment (as initia
Slide 16: Early clinical Proof-of-Mechanism – Already in Phase I
Alzstatin ® – gamma-secretase modulator Early clinical Proof-of-Mechanism – Already in Phase I • Phase I will demonstrate proof of mechanism (PoM) and central target engagement • SAD/MAD studies conducted in healthy volunteers + Alzheimer’s patients • Evaluation of safety and tolerability after sing
Slide 17: Interim phase II data on a GSM by Roche expected in 2026
Alzstatin ® – gamma-secretase modulator Interim phase II data on a GSM by Roche expected in 2026 The data is validating & increasing interest in Alzstatin® 17
Slide 18: NeuroRestore – Trk-PAM improving neuronal function & cognition in Alzheimer's disease
NeuroRestore® – Trk-PAM improving neuronal function & cognition in Alzheimer’s disease
Slide 19: The importance of BDNF & NGF signaling in Alzheimer's
NeuroRestore® – positive allosteric modulator of Trk-receptors The importance of BDNF & NGF signaling in Alzheimer’s • The neurotrophins Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) bind to their respective receptors, TrkB and TrkA and are key for brain health and cognition
Slide 20: Mechanism of Action of NeuroRestore ACD856
NeuroRestore® – positive allosteric modulator of Trk-receptors Mechanism of Action of NeuroRestore ACD856 TrkA/B • ACD856 is a novel oral small molecule positive modulator of Trk-receptors enhancing the signaling of neurotrophins such as NGF & BDNF NGF/ BDNF • The enhanced signaling leads to immedia
Slide 21: NeuroRestore – Cognitive Enhancer Improving Learning & Memory Ability
NeuroRestore® – positive allosteric modulator of Trk-receptors NeuroRestore® – Cognitive Enhancer Improving Learning & Memory Ability Stages of memory formation LEARN STORE REMEMBER Transforming information Maintaining the encoded Re-accessing the information into a form that can be stored in inform
Slide 22: Preclinical data on Pro-cognitive & Disease Modifying Effects
NeuroRestore® – positive allosteric modulator of Trk-receptors Preclinical data on Pro-cognitive & Disease Modifying Effects ACD856 improves aged-induced memory impairment • 18-months old animals were used to study effects on age-induced memory Supporting data impairment and compared to young animal
Slide 23: Phase I Demonstrated Safety, Tolerability & Target Engagement
NeuroRestore® – positive allosteric modulator of Trk-receptors Phase I Demonstrated Safety, Tolerability & Target Engagement • ACD856 is safe & well tolerated − Single and repeated dosing with ACD856 did not result in any serious adverse events in healthy volunteers at the tested dose levels • ACD85
Slide 24: Grant financed Phase IIa study to investigate safety & efficacy of ACD856 in Alzheimer's
NeuroRestore® – positive allosteric modulator of Trk-receptors Grant financed Phase IIa study to investigate the safety & efficacy of ACD856 in Alzheimer’s disease https://www.alzecurepharma.se/en/alzecure-receives-eu-grant-for-phase-2-clinical-trial-of-neurorestore-acd856-for-alzheimers-disease/ 24
Slide 25: Summary
Summary
Slide 26: Key Investment Highlights in AlzeCure
Key Investment Highlights in AlzeCure Targeting areas of significant unmet medical needs m Strong team with extensive experience and track record – from idea to clinic Platforms with first-in-class properties and potential game-changers Parallel investments in several candidates and potent follow-up
Slide 27: Karolinska Institutet Novum Science Park
Karolinska Institutet Novum Science Park Hälsovägen 7, 141 57 Stockholm SWEDEN Martin.jonsson@alzecurepharma.com www.alzecurepharma.com
AlzeCure Pharma — Redeye Theme: Alzheimer's (April 2026) on 6ix